The efficacy of emamectin benzoate as an oral treatment of sea lice, Lepeophtheirus salmonis (KrÒyer), infestations in Atlantic salmon, Salmo salar L., was evaluated in a dose titration study and two dose confirmation studies. Replicated groups of salmon with induced infestations of sea lice were given emamectin benzoate on pelleted feed at doses of 0, 25, 50 and 100 μg kg−1 biomass day−1 for seven consecutive days. Sea lice were counted at 7, 14 and 21 days from the start of treatment, and comparisons made with control fish given the same diet without emamectin benzoate. Total numbers of sea lice were significantly reduced at all doses in all three studies when compared to control fish. There was no significant difference between doses of 50 and 100 μg kg−1, but the 50 μg kg−1 dose resulted in significantly fewer lice than the 25 μg kg−1 dose. Emamectin benzoate was highly effective in reducing numbers of preadult and adult lice and prevented the maturation of chalimus to motile stages. The optimum therapeutic dose was selected as 50 μg kg−1 day−1 for seven days. Treatment reduced the incidence of epidermal damage by sea lice and, in one study, survival of treated fish was 48% higher than in control groups. No fish mortalities or adverse effects were attributed to treatment with emamectin benzoate at any of the doses tested.

The duration of efficacy of emamectin benzoate in the oral treatment of sea lice, Lepeophtheirus salmonis, infesting Atlantic salmon, Salmo salar L., was evaluated in a tank study. One group of salmon was treated at a nominal dose of 50 μg kg−1 biomass day−1 for 7 consecutive days and a second group was untreated. Fish were then redistributed to 16 tanks, each holding 17 control and 17 treated fish. On days 34, 41, 48, 55, 62, 69, 76 and 83, two tanks were challenged with L. salmonis copepodites. Eight to 14 days after each challenge, fish were anaesthetized and numbers of lice recorded. Treatment with emamectin benzoate prevented development of copepodites for up to 62 days from the start of treatment, and chalimus numbers remained low for 69 days. Treated fish, challenged from days 34 to 69, had significantly (P<0.01) fewer lice than control fish. Treated fish challenged at days 76 and 83 still had fewer lice than control groups, although differences were not statistically significant for both replicates. When chalimus appeared on treated fish challenged at days 69–83, survival of chalimus to adult stages was lower than on control fish. Louse egg production on treated fish challenged at days 62–83 was not reduced compared to control groups.

No abstract

No abstract

Abstract. The efficacy of florfenicol against laboratory‐induced infection with Aeromonas salmonicida was tested in Atlantic salmon, Salmo salar L., parr. Medication at three dose levels in the feed was started 24 h after bath challenge with A. salmonicida. The specific mortality rate in the unprotected infected control group was 75% compared with 5, 13 and 17% when florfenicol was given at dose levels of 20, 10 and 5 mg per kg body weight per day, respectively. Florfenicol was palatable to the fish at doses in excess of effective therapeutic levels and feeding for 10 days at 100 mg per kg, or for prolonged periods at 50 mg per kg and 10 mg per kg, resulted in no feeding problems or histopathological abnormalities. Florfenicol appears to have a good therapeutic index and considerable potential in the control of furunculosis in salmon.